Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

utical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainty whether the clinical trial results will allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:
    David Schull or Wendy La
'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 In a recent study ... backflow of the Eldor spinal needle 25G, 103 mm ... pencil point spinal needles of the same gauge and ... anesthesia is an excellent type of regional anesthesia for ... etc. It is estimated that 100 million ...
(Date:9/30/2014)... September 2014 ... Acutus Medical, Inc. ... 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit zur ... komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen bzw. ... zusätzlichen Finanzierung über 26,2 Mio. USD ...
(Date:9/30/2014)... Sept. 30, 2014  The orthopedic specialists at Midwest ... 6 orthopedic group by US News & World Report, ... series of free, public seminars to discuss partial and ... world come to see the knee physicians at Midwest ... available at Munster Specialty Surgery Center. ...
Breaking Medicine Technology:Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2
... 20 In an effort to ... supply chain, Siemens Healthcare Diagnostics (Siemens) has published product data ... U.S. product line into the GHX Health ConneXion(SM) data pool. ... GS1,s Global Data Synchronization Network (GDSN®) that is focused solely ...
... Kinetic Systems, Inc., a leading global provider of process ... clients, announced today the appointment of Peter M. Maris ... to its Board of Directors. He will also continue ... Mr. Maris has been with Kinetics for more than ...
Cached Medicine Technology:Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool 2Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool 3Kinetic Systems Appoints Peter M. Maris President & Chief Executive Officer 2
(Date:9/30/2014)... 30, 2014 This two-day, advanced ... vestibular sequellae that may arise following a concussion ... concussions can be varied, from sports related injuries, car ... sustained by the thousands of returning soldiers from war ... blast and blunt traumas can result in similar injuries, ...
(Date:9/30/2014)... Amy Norton ... News) -- Long-acting contraceptive devices should be the first ... from the American Academy of Pediatrics state. Although ... pills, two other forms of contraception -- intrauterine devices ... according to the academy. And they should be ...
(Date:9/30/2014)... HealthDay Reporter , MONDAY, Sept. ... broad-spectrum antibiotics before the age of 2 may face ... new research suggests. Broad-spectrum antibiotics target a larger ... study. "It is a reason to think about ... picking," said lead researcher Dr. Charles Bailey, attending physician ...
(Date:9/30/2014)... Thompson HealthDay Reporter MONDAY, ... receive medical implants -- artificial valves, hip replacements, surgical mesh ... tested before or after their approval by the U.S. Food ... -- conducted by prominent nonprofit groups and published online Sept. ... blame for inadequate medical device testing on lax oversight by ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... provider in the nation, today announced that Adam ... Healthcare’s anesthesiology division, will present at the Society ... SHSMD Connections 2014 . The conference will ... , SHSMD Connections is a four-day conference that ...
Breaking Medicine News(10 mins):Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3
... has announced,the appointment of Florence L. DiBenedetto as senior ... January 5, 2009, succeeding longtime,General Counsel Gary Loveridge who ... Formerly senior partner of the Sacramento-based law firm Hunter ... decades, DiBenedetto,served for more than 10 years as the ...
... Progressive Lenses and Transitions® Lenses to Produce Optimal Visual Experience ... ... Two of the most distinguished names in the optical industry are ... ,Carl Zeiss Vision, a leader for 160 years in precision optics, ...
... Dec. 17 Hologic, Inc. (Nasdaq: HOLX ), ... imaging systems and surgical products dedicated to serving the healthcare ... quarter fiscal 2009 operating results on Monday, February 2, 2009 ... host a conference call on Monday, February 2, 2009 at ...
... eggs to fertility clinics reported satisfaction with the process, ... 20 percent reported lasting psychological effects, according to the ... , The research by scientists at the University of ... 20 states and is the largest study to explore ...
... 1 Million Prescriptions , , ... wholly owned subsidiary of the Cystic Fibrosis Foundation, today announced ... cystic fibrosis (CF) community nationwide. , , ... patient, one prescription and a mission to improve access to ...
... to Meet Joint Commission Compliance through Patient Engagement , ... In an effort to improve patient safety and standards ... Patient Care (IPC) solutions, is enabling King,s Daughters Medical Center ... Patient Safety Goal (NPSG) 16 through GetWellNetwork,s interactive PatientLife ...
Cached Medicine News:Health News:Sutter Health Welcomes New General Counsel 2Health News:Carl Zeiss Vision and Transitions Optical Inc. Promote Pioneering Eyewear to Consumers 2Health News:Hologic, Inc. to Release First Quarter Fiscal 2009 Operating Results on Monday, February 2, 2009 2Health News:Most women report satisfaction with egg donation; some claim problems 2Health News:Most women report satisfaction with egg donation; some claim problems 3Health News:Cystic Fibrosis Services Pharmacy Celebrates 20th Anniversary 2Health News:King's Daughters Medical Center Leverages Unique Bedside Interactive Technology to Meet Requirements of Patient Safety Goal 16 2Health News:King's Daughters Medical Center Leverages Unique Bedside Interactive Technology to Meet Requirements of Patient Safety Goal 16 3
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Inquire...
Inquire...
Inquire...
Medicine Products: